PODD
ACHAT TOTAL: 1 100 titres (~162 217,00 $ US)
- Insiders
- McEvoy Ashley
- Total bought
- $162,217
- Total sold
- —
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-27
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.6% | 69.8% | 68.3% | 61.7% | 68.4% | |
| Ebit Margin | 15.5% | 16.6% | 14.8% | 3.5% | 7.5% | |
| Ebitda Margin | 19.7% | 20.5% | 19.1% | 8.4% | 12.7% | |
| Operating Profit Margin | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | |
| Pretax Profit Margin | 12.5% | 14.5% | 12.6% | 0.8% | 1.9% | |
| Continuous Operations Profit Margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | |
| Net Profit Margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | |
| Bottom Line Profit Margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | |
| Current Ratio | 2.777 | 3.541 | 3.471 | 3.561 | 5.754 | |
| Quick Ratio | 2.112 | 2.727 | 2.579 | 2.610 | 4.429 | |
| Solvency Ratio | 0.215 | 0.266 | 0.150 | 0.038 | 0.050 | |
| Cash Ratio | 1.053 | 1.804 | 1.442 | 1.711 | 3.460 | |
| Price To Earnings Ratio | 80.980 | 43.730 | 73.304 | 4,440.271 | 1,064.280 | |
| Price To Earnings Growth Ratio | -1.965 | 0.430 | 0.017 | -60.428 | 8.362 | |
| Forward Price To Earnings Growth Ratio | -1.965 | 0.430 | 0.017 | -60.428 | 8.362 | |
| Price To Earnings Diluted Ratio | 81.678 | 45.168 | 73.803 | 4,474.012 | 1,064.280 | |
| Price To Earnings Diluted Growth Ratio | -2.053 | 0.468 | 0.017 | -60.722 | 7.095 | |
| Price To Book Ratio | 13.197 | 15.100 | 20.656 | 42.870 | 32.379 | |
| Price To Sales Ratio | 7.384 | 8.831 | 8.918 | 15.646 | 16.393 | |
| Price To Free Cash Flow Ratio | 52.941 | 59.904 | 215.900 | -533.246 | -94.405 | |
| Price To Operating Cash Flow Ratio | 35.123 | 42.516 | 103.875 | 171.624 | -264.499 | |
| Debt To Assets Ratio | 0.329 | 0.461 | 0.560 | 0.636 | 0.628 | |
| Debt To Equity Ratio | 0.694 | 1.174 | 1.977 | 3.008 | 2.313 | |
| Debt To Capital Ratio | 0.410 | 0.540 | 0.664 | 0.750 | 0.698 | |
| Long Term Debt To Capital Ratio | 0.393 | 0.517 | 0.651 | 0.743 | 0.692 | |
| Financial Leverage Ratio | 2.106 | 2.548 | 3.532 | 4.725 | 3.683 | |
| Working Capital Turnover Ratio | 2.123 | 1.686 | 1.656 | 1.291 | 1.038 | |
| Operating Cash Flow Ratio | 0.837 | 0.814 | 0.323 | 0.326 | -0.298 | |
| Operating Cash Flow Sales Ratio | 0.210 | 0.208 | 0.086 | 0.091 | -0.062 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.663 | 0.710 | 0.481 | -0.322 | 2.802 | |
| Debt Service Coverage Ratio | 4.317 | 4.213 | 3.539 | 1.547 | 1.480 | |
| Interest Coverage Ratio | 5.945 | 7.234 | 6.077 | 1.044 | 2.042 | |
| Short Term Operating Cash Flow Coverage Ratio | 25.644 | 5.009 | 2.754 | 3.826 | -2.262 | |
| Operating Cash Flow Coverage Ratio | 0.542 | 0.303 | 0.101 | 0.083 | -0.053 | |
| Capital Expenditure Coverage Ratio | 2.971 | 3.445 | 1.927 | 0.757 | -0.555 | |
| Dividend Paid And Capex Coverage Ratio | 2.971 | 3.445 | 1.927 | 0.757 | -0.555 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 38.194 | 44.284 | 49.236 | 194.791 | 132.574 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.6% | ▲1.8% | ▲3.6% |
| Ebit Margin | 15.5% | ▼-1.1% | ▲3.9% |
| Ebitda Margin | 19.7% | ▼-0.8% | ▲3.6% |
| Operating Profit Margin | 17.5% | ▲2.6% | ▲5.5% |
| Pretax Profit Margin | 12.5% | ▼-1.9% | ▲4.1% |
| Continuous Operations Profit Margin | 9.1% | ▼-11.1% | ▲0.4% |
| Net Profit Margin | 9.1% | ▼-11.1% | ▲0.4% |
| Bottom Line Profit Margin | 9.1% | ▼-11.1% | ▲0.4% |
| Current Ratio | 2.777 | ▼-0.764 | ▼-1.044 |
| Quick Ratio | 2.112 | ▼-0.615 | ▼-0.780 |
| Solvency Ratio | 0.215 | ▼-0.051 | ▲0.071 |
| Cash Ratio | 1.053 | ▼-0.751 | ▼-0.841 |
| Price To Earnings Ratio | 80.980 | ▲37.250 | ▼-1059.533 |
| Price To Earnings Growth Ratio | -1.965 | ▼-2.395 | ▲8.752 |
| Forward Price To Earnings Growth Ratio | -1.965 | ▼-2.395 | ▲8.752 |
| Price To Earnings Diluted Ratio | 81.678 | ▲36.510 | ▼-1066.110 |
| Price To Earnings Diluted Growth Ratio | -2.053 | ▼-2.520 | ▲8.986 |
| Price To Book Ratio | 13.197 | ▼-1.903 | ▼-11.643 |
| Price To Sales Ratio | 7.384 | ▼-1.448 | ▼-4.051 |
| Price To Free Cash Flow Ratio | 52.941 | ▼-6.963 | ▲112.722 |
| Price To Operating Cash Flow Ratio | 35.123 | ▼-7.393 | ▲17.395 |
| Debt To Assets Ratio | 0.329 | ▼-0.131 | ▼-0.194 |
| Debt To Equity Ratio | 0.694 | ▼-0.480 | ▼-1.139 |
| Debt To Capital Ratio | 0.409 | ▼-0.130 | ▼-0.203 |
| Long Term Debt To Capital Ratio | 0.393 | ▼-0.124 | ▼-0.206 |
| Financial Leverage Ratio | 2.106 | ▼-0.443 | ▼-1.213 |
| Working Capital Turnover Ratio | 2.123 | ▲0.437 | ▲0.564 |
| Operating Cash Flow Ratio | 0.837 | ▲0.023 | ▲0.436 |
| Operating Cash Flow Sales Ratio | 0.210 | ▲0.003 | ▲0.104 |
| Free Cash Flow Operating Cash Flow Ratio | 0.663 | ▼-0.046 | ▼-0.203 |
| Debt Service Coverage Ratio | 4.317 | ▲0.104 | ▲1.298 |
| Interest Coverage Ratio | 5.945 | ▼-1.289 | ▲1.476 |
| Short Term Operating Cash Flow Coverage Ratio | 25.644 | ▲20.635 | ▲18.650 |
| Operating Cash Flow Coverage Ratio | 0.542 | ▲0.239 | ▲0.347 |
| Capital Expenditure Coverage Ratio | 2.971 | ▼-0.474 | ▲1.262 |
| Dividend Paid And Capex Coverage Ratio | 2.971 | ▼-0.474 | ▲1.262 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 38.194 | ▼-6.091 | ▼-53.622 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $20.00B | $18.29B | $15.13B | $20.42B | $18.01B | |
| Enterprise value | $20.33B | $18.76B | $15.93B | $21.23B | $18.51B | |
| EV / Sales | 7.51x | 9.06x | 9.39x | 16.27x | 16.84x | |
| EV / Op. cash flow | 35.71x | 43.60x | 109.35x | 178.42x | -271.77x | |
| EV / Free cash flow | 53.83x | 61.44x | 227.28x | -554.37x | -97.00x | |
| EV / EBITDA | 38.19x | 44.28x | 49.24x | 194.79x | 132.57x | |
| Net debt / EBITDA | 0.63x | 1.11x | 2.47x | 7.42x | 3.54x | |
| Current ratio | 2.78x | 3.54x | 3.47x | 3.56x | 5.75x | |
| Income quality | 2.30x | 1.03x | 0.71x | 25.87x | -4.05x | |
| Graham number | $41 | $48 | $26 | $3 | $7 | |
| Graham net-net | -$5 | -$6 | -$10 | -$11 | -$6 | |
| Tax burden | 72.8% | 139.3% | 96.1% | 46.9% | 82.0% | |
| Interest burden | 81.0% | 87.5% | 85.6% | 21.4% | 24.9% | |
| Working capital | $1.21B | $1.34B | $1.12B | $934.1M | $1.09B | |
| Invested capital | $2.24B | $2.25B | $1.96B | $1.69B | $1.71B | |
| Return on assets | 7.7% | 13.5% | 8.0% | 0.2% | 0.8% | |
| Operating ROA | 15.1% | 10.9% | 9.1% | 1.7% | 6.4% | |
| Return on tangible assets | 8.2% | 14.2% | 8.5% | 0.2% | 0.9% | |
| Return on equity | 16.3% | 34.5% | 28.2% | 1.0% | 3.0% | |
| Return on invested capital | 13.6% | 11.7% | 9.7% | 0.9% | 5.6% | |
| Return on capital employed | 18.9% | 12.1% | 10.3% | 2.0% | 6.9% | |
| Earnings yield | 1.2% | 2.3% | 1.4% | 0.0% | 0.1% | |
| Free cash flow yield | 1.9% | 1.7% | 0.5% | -0.2% | -1.1% | |
| Capex / Op. cash flow | 33.7% | 29.0% | 51.9% | 132.2% | -180.2% | |
| Capex / Depreciation | 211.9% | 154.6% | 103.8% | 248.9% | 213.8% | |
| Capex / Sales | 7.1% | 6.0% | 4.5% | 12.1% | 11.2% | |
| SG&A / Sales | 43.0% | 44.3% | 43.3% | 45.0% | 42.4% | |
| R&D / Sales | 11.1% | 10.6% | 12.1% | 13.8% | 14.6% | |
| Stock comp / Sales | 2.3% | 3.3% | 2.8% | 3.1% | 3.1% | |
| Intangibles / Total assets | 5.3% | 4.9% | 5.8% | 5.7% | 3.7% | |
| Days sales outstanding | 70d | 64d | 77d | 57d | 53d | |
| Days payables outstanding | 36d | 12d | 13d | 22d | 40d | |
| Operating cycle | 285d | 315d | 351d | 311d | 373d | |
| Cash conversion cycle | 249d | 304d | 338d | 288d | 333d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+9.3%EV / Sales ▼-17.1%EV / EBITDA ▼-13.8%EV / Op. cash flow ▼-7.894Earnings yield ▼-0.011Graham number ▼-6.930
Profitability
Return on equity ▼-0.182Return on assets ▼-0.058Return on invested capital ▲+0.019Return on capital employed ▲+0.068Operating ROA ▲+0.042Income quality ▲+1.275Tax burden ▼-0.666
Efficiency
Days sales outstanding ▲+5.270Days payables outstanding ▲+24.089Operating cycle ▼-30.675Cash conversion cycle ▼-54.764Capex / Sales ▲+0.010R&D / Sales ▲+0.005
Balance-sheet strength
Current ratio ▼-0.764Net debt / EBITDA ▼-0.477Working capital ▼-134200000.000Invested capital ▼-12100000.000Intangibles / Total assets ▲+0.004
Change over 5 years
Valuation
Market cap ▲+11.0%EV / Sales ▼-55.4%EV / EBITDA ▼-71.2%EV / Op. cash flow ▲+307.478Earnings yield ▲+0.011Graham number ▲+34.485
Profitability
Return on equity ▲+0.133Return on assets ▲+0.069Return on invested capital ▲+0.080Return on capital employed ▲+0.120Operating ROA ▲+0.087Income quality ▲+6.357Tax burden ▼-0.092
Efficiency
Days sales outstanding ▲+16.187Days payables outstanding ▼-4.055Operating cycle ▼-87.970Cash conversion cycle ▼-83.915Capex / Sales ▼-0.041R&D / Sales ▼-0.035
Balance-sheet strength
Current ratio ▼-2.977Net debt / EBITDA ▼-2.916Working capital ▲+120900000.000Invested capital ▲+530000000.000Intangibles / Total assets ▲+0.016
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-04 | Ro Khanna | Purchase | $1,000 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $15,001 - $50,000 |
Recent news
- 2026-08-26 PODD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Insulet Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 31 Deadline in Securities Class Action - PODD New York, New York--(Newsfile Corp. - August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline. SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-26 Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - August 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period").
- 2026-08-26 Faruqi & Faruqi, LLP Urges Insulet Corporation (NASDAQ: PODD) Investors to Seek Counsel Before the August 31, 2026 Lead Plaintiff Deadline in the Securities Class Action Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Insulet to Contact Him Directly to Discuss Their Options NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP , a leading national securities law firm, reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD). [You may also click here for additional information] WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”).
- 2026-08-26 PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact Levi & Korsinsky Confidence in Insulet''s Manufacturing Story Collapsed After Two Omnipod Recalls Exposed Quality Failures Resulting in Analysts Questioning the Scope of Insulet''s Manufacturing and Quality-Control Issues NEW YORK, Aug. 26, 2026 /PRNewswire/ -- When BTIG slashed its valuation multiple on Insulet Corporation (NASDAQ: PODD) from approximately 4.5x to 4x on May 26, 2026, analysts cited "continued negative investor sentiment" and "some risk of reputation damage or increased regulatory scrutiny" from the company''s second voluntary medical device correction in less than three months. The next day, Goldman Sachs went further, writing that it did "not fully subscribe to the reiteration of guidance" and had "lowered estimates accordingly.
- 2026-08-26 MONDAY INVESTOR DEADLINE: Insulet Corporation (PODD) Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces SAN DIEGO--(BUSINESS WIRE)---- $PODD #Insulet--The case alleges Insulet and certain of its top executives made false and/or misleading statements to investors.
- 2026-08-26 SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Insulet Corporation (PODD) NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive. Should You Join The Insulet Class Action Lawsuit : Do you, or did you, own shares of Insulet Corporation (NASDAQ: PODD)?
- 2026-08-26 PODD INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the August 31, 2026 Lead Plaintiff Deadline in the Insulet Corporation Securities Class Action ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Insulet Corporation (“Insulet”) (NASDAQ: PODD). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Insulet''s business, operations, and compliance policies, including allegations that: (i) Insulet''s manufacturing controls and procedures were defective; and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.
- 2026-08-26 Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insu.
- 2026-08-25 Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers – PODD NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 26-cv-13062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants'' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 2026-08-25 Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Insulet Corporation. IF YOU SUFFERED A LOSS ON YOUR INSULET CORPORATION INVESTMENTS, CLICK HERE BEFORE AUGUST 31, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?